Abstract

Candida haemulonii complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) is well-known for its resistance profile to different available antifungal drugs. Although echinocandins are the most effective class of antifungal compounds against the C. haemulonii species complex, clinical isolates resistant to caspofungin, micafungin and anidulafungin have already been reported. In this work, we present a literature review regarding the effects of echinocandins on this emergent fungal complex. Published data has revealed that micafungin and anidulafungin were more effective than caspofungin against the species forming the C. haemulonii complex. Subsequently, we investigated the susceptibilities of both planktonic and biofilm forms of 12 Brazilian clinical isolates of the C. haemulonii complex towards caspofungin and micafungin (anidulafungin was unavailable). The planktonic cells of all the fungal isolates were susceptible to both of the test echinocandins. Interestingly, echinocandins caused a significant reduction in the biofilm metabolic activity (viability) of almost all fungal isolates (11/12, 91.7%). Generally, the biofilm biomasses were also affected (reduction range 20–60%) upon exposure to caspofungin and micafungin. This is the first report of the anti-biofilm action of echinocandins against the multidrug-resistant opportunistic pathogens comprising the C. haemulonii complex, and unveils the therapeutic potential of these compounds.

Highlights

  • The members of the Candida haemulonii species complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) are well-known for theirdrug-resistance towards several antifungal agents available in clinical practice

  • Susceptibility to prescribed echinocandins is commonly observed [7,8,9,10,11], there have been some reports of clinical isolates being resistant to these compounds [5,12]

  • Considering the aforementioned aspects, the aim of the present study was to evaluate the antifungal susceptibility of both planktonic- and biofilm-forming cells from 12 Brazilian clinical isolates comprising the C. haemulonii complex towards caspofungin and micafungin

Read more

Summary

Introduction

The members of the Candida haemulonii species complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) are well-known for their (multi)drug-resistance towards several antifungal agents available in clinical practice. Vulnera) are well-known for their (multi)drug-resistance towards several antifungal agents available in clinical practice. Resistance of the C. haemulonii complex to azoles (e.g., fluconazole, itraconazole and voriconazole) and polyenes (e.g., amphotericin B) has been documented extensively [1,2,3,4,5,6,7]. Echinocandins are the newest class of antifungal agents to be used in clinical practice, exhibiting fungicidal activity against yeasts as well as having a good safety profile [8]. In this sense, the guidelines of the Centers for Disease Control and Prevention (CDC, USA) strongly recommend that echinocandins.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call